Aimmune Therapeutics Inc. (AIMT)

22.35
0.87 3.70
NASDAQ : Health Technology
Prev Close 23.22
Open 22.95
Day Low/High 22.33 / 23.21
52 Wk Low/High 16.95 / 36.12
Volume 902.50K
Avg Volume 708.90K
Exchange NASDAQ
Shares Outstanding 62.67M
Market Cap 1.55B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting To Discuss PALFORZIA™ (AR101) For Peanut Allergy

Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting To Discuss PALFORZIA™ (AR101) For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company's common stock.

If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength

If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength

AIMT lacks a strong and developed base, so only small long positions should be bought.

What's It Worth to You?: Cramer's 'Mad Money' Recap (Monday 9/9/19)

What's It Worth to You?: Cramer's 'Mad Money' Recap (Monday 9/9/19)

Jim Cramer says investors are reevaluating how much they're willing to pay for growth today and for a company's growth in the future.

Waste Management, Vail Resorts, B&G Foods: 'Mad Money' Lightning Round

Waste Management, Vail Resorts, B&G Foods: 'Mad Money' Lightning Round

Jim Cramer takes a look at Waste Management, Vail Resorts, Aimmune Therapeutics, Comstock Resources, B&G Foods and more.

Aimmune Enrolls First Patient In Phase 2 Trial Of AR201 For Egg Allergy

Aimmune Enrolls First Patient In Phase 2 Trial Of AR201 For Egg Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg...

Interesting AIMT Put And Call Options For October 18th

Interesting AIMT Put And Call Options For October 18th

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the October 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new October 18th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics Announces Second Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics Announces Second Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2019.

Aimmune To Present At The Wedbush PacGrow Healthcare Conference

Aimmune To Present At The Wedbush PacGrow Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss Second Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss Second Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, August 8, 2019, at 4:30 p.

Aimmune Statement On Institute For Clinical And Economic Review (ICER) Final Report On AR101 For Peanut Allergy

Aimmune Statement On Institute For Clinical And Economic Review (ICER) Final Report On AR101 For Peanut Allergy

Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, cautions stakeholders against drawing conclusions from the Institute for Clinical and Economic Review's (ICER's) final report on...

First Week Of AIMT August 16th Options Trading

First Week Of AIMT August 16th Options Trading

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Aimmune Submits Marketing Authorization Application To European Medicines Agency For AR101 For Peanut Allergy

Aimmune Submits Marketing Authorization Application To European Medicines Agency For AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for...

Aimmune To Present At The JMP Securities Life Sciences Conference

Aimmune To Present At The JMP Securities Life Sciences Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.

Aimmune Therapeutics Discusses AR101's Cost-Effectiveness And Demonstrated Clinical Benefits At ICER Meeting

Aimmune Therapeutics Discusses AR101's Cost-Effectiveness And Demonstrated Clinical Benefits At ICER Meeting

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Institute for Clinical and Economic Review's (ICER) Public Meeting reviewing the effectiveness and value...

Aimmune To Participate In The Goldman Sachs 40th Annual Healthcare Conference

Aimmune To Participate In The Goldman Sachs 40th Annual Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40 th...

Stocks Take Flight on Dovish Fed Comments

Stocks Take Flight on Dovish Fed Comments

Market players are trying to decipher Fed Chair Powell's latest words.

Data From Two Studies Confirm Quality Of Life And Psychosocial Burden Of Living With Peanut Allergy

Data From Two Studies Confirm Quality Of Life And Psychosocial Burden Of Living With Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced new data from two studies that assessed the psychosocial burden of living with peanut allergy.

New Data From Phase 3 PALISADE Follow-on Study Of AR101 For Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year

New Data From Phase 3 PALISADE Follow-on Study Of AR101 For Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results from ARC004, an open-label, rollover study of the landmark Phase 3 PALISADE trial, which showed that...

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety And Efficacy Of AR101 In Children And Adolescents With Peanut Allergy

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety And Efficacy Of AR101 In Children And Adolescents With Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had...

First Week Of July 19th Options Trading For Aimmune Therapeutics (AIMT)

First Week Of July 19th Options Trading For Aimmune Therapeutics (AIMT)

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Aimmune To Present AR101 Data At European Academy Of Allergy And Clinical Immunology 2019 Congress

Aimmune To Present AR101 Data At European Academy Of Allergy And Clinical Immunology 2019 Congress

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient quality of life data at the European Academy of Allergy and Clinical...

New Study Shows More Than Half Of Teens With Peanut Allergy Visited The E.R., More Than One-Third Required Hospitalization Due To Accidental Exposure To Peanut

New Study Shows More Than Half Of Teens With Peanut Allergy Visited The E.R., More Than One-Third Required Hospitalization Due To Accidental Exposure To Peanut

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results of a new study of U.

Aimmune To Present At RBC Capital Markets Global Healthcare Conference

Aimmune To Present At RBC Capital Markets Global Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare...

Aimmune Announces U.S. FDA Advisory Committee Meeting Date For AR101 For Peanut Allergy

Aimmune Announces U.S. FDA Advisory Committee Meeting Date For AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.

Aimmune Therapeutics Announces First Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics Announces First Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter ended March 31, 2019.

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss First Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss First Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.

Giddiness Eludes

No indicators to support giddiness as breadth improves, small caps join the party, and number of new highs looks pretty small.

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

There is a bloodbath of selling in medical-related names and severe pressure on cloud-related stocks that have been momentum favorites.